Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555955 · ClinicalTrials.gov registry record · Phase 1
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03555955 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT03555955, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
Interventions
- DRUG CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2021-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03555955
The ClinicalTrials.gov registry entry for NCT03555955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPX-351 is the first listed.
NCT03555955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03555955 about?
NCT03555955 is a clinical study titled "A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351". This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
What is the current status of trial NCT03555955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-11-20. Estimated completion is 2021-05-26.
What interventions are being tested in trial NCT03555955?
The interventions under investigation include: CPX-351 (DRUG).
Who is sponsoring clinical trial NCT03555955?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.